Alos Biosciences

Overview

Overview

Alos Biosciences is a Colombian biotechnology company focused on developing treatments for neurodegenerative diseases["1"]. Based in Bogotá, Alos represents Colombia's emerging biotech sector in neuroscience research. The company was founded with a mission to address the significant unmet medical need in Parkinson's disease and related disorders that affect millions of people worldwide.

Colombia represents a strategically important location for neurodegenerative disease research due to the presence of unique population genetics, including families with hereditary Parkinson's disease, and strong academic partnerships with institutions studying Latin American populations [@devenney2017]. Alos Biosciences leverages these local resources while maintaining international collaborations to advance novel therapeutic candidates.

Company Mission and Vision

Alos Biosciences aims to develop disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders. The company's approach focuses on targeting core pathological mechanisms rather than just symptomatic relief. By developing novel small molecules and biologics, Alos seeks to address the underlying disease processes that cause progressive neuronal loss in these devastating conditions [@wong2021].

Research Focus

Alpha-Synuclein Aggregation Inhibitors

The company's primary research focus is on developing inhibitors of alpha-synuclein aggregation. In Parkinson's disease, the misfolding and aggregation of alpha-synuclein protein into Lewy bodies represents a hallmark pathological feature that drives disease progression [@brava2020]. Alos is working on small molecule compounds that can prevent the formation of toxic oligomers and fibrils, potentially slowing or halting disease progression [@fielding2023].

Research efforts include:

• Small molecule inhibitors: Developing brain-penetrant compounds that bind to alpha-synuclein and prevent its pathological aggregation
• Protein-protein interaction blockers: Targeting interactions between alpha-synuclein and other proteins that promote aggregation
• Aggregation seed inhibitors: Compounds that can neutralize existing aggregation seeds and prevent template-directed misfolding

Neuroprotective Small Molecules

Beyond alpha-synuclein targeting, Alos develops neuroprotective agents that can support neuronal survival and function. These approaches include:

• Mitochondrial protectors: Compounds that maintain mitochondrial function and prevent energy failure in dopaminergic neurons [@foltnie2022]
• Anti-inflammatory agents: Molecules that reduce neuroinflammation without compromising normal immune function [@obrien2021]
• Autophagy enhancers: Compounds that promote clearance of damaged proteins and organelles through enhanced cellular recycling [@vasili2019]

Parkinson's Disease Biomarkers

Biomarker development is a key component of Alos's research program. The company is working on diagnostic and prognostic biomarkers that can:

• Enable early diagnosis of Parkinson's disease before significant motor symptoms appear [@morton2022]
• Track disease progression and treatment response
• Identify patients most likely to respond to specific therapies [@espay2020]
• Support clinical trial enrichment and endpoint measurement [@simon2020]

Pipeline Overview

Preclinical Programs

Alos Biosciences has several compounds in various stages of preclinical development:

| Program | Target | Stage | Indication |
|---------|--------|-------|------------|
| ALOS-101 | Alpha-synuclein aggregation | Lead optimization | Parkinson's disease |
| ALOS-202 | Neuroinflammation | Hit-to-lead | Parkinson's disease |
| ALOS-303 | Mitochondrial function | Discovery | Multiple system atrophy |
| ALOS-401 | Autophagy enhancement | Discovery | Parkinson's disease |

Research Collaborations

The company maintains active research collaborations with:

• Universidad de los Andes (Bogotá): Basic neuroscience research and animal models
• Institute of Neurology, University College London: Alpha-synuclein biology and biomarker development
• Parkinson's Foundation Centers of Excellence: Clinical insights and patient access
• Spanish Parkinson's disease research network: European regulatory expertise

Scientific Advisory Board

Alos benefits from guidance from international scientific advisors with expertise in:

• [Alpha-synuclein](/proteins/alpha-synuclein) biology and propagation mechanisms
• Clinical neurology and movement disorders
• Drug discovery and development
• Biomarker development and validation

Market Opportunity

Parkinson's disease affects approximately 10 million people worldwide, with prevalence increasing with age [@kalia2015]. The global Parkinson's disease therapeutic market exceeds $20 billion annually, with significant unmet need for disease-modifying therapies that can slow or halt progression rather than just treat symptoms.

Current treatments include:

• [Dopamine](/mechanisms/dopaminergic-signaling) replacement therapy (levodopa, dopamine agonists)
• MAO-B inhibitors
• COMT inhibitors
• Deep brain stimulation

Technology Platform

Alos employs several proprietary technologies in its drug discovery efforts:

Structure-Based Design

The company uses computational modeling and structural biology to design small molecules that specifically target pathological conformations of alpha-synuclein and related proteins. This approach allows for rational drug design rather than high-throughput screening alone.

In Vitro Aggregation Assays

Alos has developed sensitive assays to measure alpha-synuclein aggregation kinetics and the effects of test compounds on these processes. These assays use multiple detection methods including Thioflavin T fluorescence, dynamic light scattering, and atomic force microscopy.

In Vivo Models

The company collaborates with academic partners to test lead compounds in relevant animal models of Parkinson's disease, including toxin-based models (MPTP, 6-OHDA) and genetic models (alpha-synuclein transgenic mice).

Intellectual Property

Alos maintains an active patent portfolio covering:

• Novel small molecule compositions of matter
• Methods of use for specific indications
• Biomarker combinations for patient selection
• Treatment regimens and dosing protocols

Competitive Landscape

Key competitors in the Parkinson's disease drug development space include:

| Company | Approach | Stage |
|---------|----------|-------|
| Roche/Genentech | Alpha-synuclein antibody | Phase 3 |
| Biogen | Alpha-synuclein antibody | Phase 2 |
| AbbVie | Alpha-synuclein antibody | Phase 2 |
| Novartis | LRRK2 inhibitor | Phase 1/2 |
| Denali | LRRK2 inhibitor | Phase 1 |
| Alos Biosciences | Small molecule aggregation inhibitors | Preclinical |

Alos's small molecule approach offers potential advantages including oral bioavailability, potentially lower cost of goods, and different mechanism of action that may be complementary to antibody approaches.

Future Directions

Alos Biosciences plans to advance its lead program into clinical development by 2027, with the following milestones:

The company is actively seeking strategic partnerships with pharmaceutical companies to accelerate development and maximize the global reach of its potential therapies.

International Collaboration

Alos partners with research institutions in Spain and the United States for drug development programs. These partnerships provide access to:

• Specialized research expertise
• Clinical trial infrastructure
• Regulatory guidance from major pharmaceutical regulatory agencies
• International patient populations for clinical trials

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Neurodegeneration Mechanisms](/diseases/neurodegeneration)
• [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)

References

External Links

• [Alos Biosciences Website](https://alosbio.com/)
• [PubMed - Parkinson's Disease Research](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov - Parkinson's Disease](https://clinicaltrials.gov)

Pathway Diagram

The following diagram shows the key molecular relationships involving Alos Biosciences discovered through SciDEX knowledge graph analysis: